Fig. 4

Correlation of CD79B and PIM1 mutations with BTK and pan-PIM inhibitors response. (a) BTK inhibitor (Ibrutinib) and pan-PIM inhibitor (AZD 1208) showed a dose- and time-dependent growth inhibition in DLBCL cell lines. (b) CD79B-mutant Val cells and PIM1-mutant OCI-Ly8 cells were more susceptible to Ibrutinib (10 μM)- and AZD 1208 (40 μM)-induced growth inhibition (p < 0.01). (c) and (d) CD79B-mutant Val cells and PIM1-mutant OCI-Ly8 cells were more sensitive to Ibrutinib (10 μM)- and AZD 1208 (40 μM)-induced apoptosis (p < 0.01)